Article Per Year (5 Year)
p-Index From 2019 - 2024
1.953
P-Index
This Author published in this journals
All Journal Folia Medica Indonesiana Jurnal Farmasi Klinik Indonesia INDONESIAN JOURNAL OF PHARMACY JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Jurnal Pengabdian Pada Masyarakat JFIOnline JURNAL MEDIA KESEHATAN Majalah Farmasetika Indian Journal of Forensic Medicine & Toxicology
Budi Suprapti
Department Of Pharmacy Practice, Faculty Of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
Agriculture, Biological Sciences & Forestry Chemistry Decision Sciences, Operations Research & Management Education Engineering Health Professions Medicine & Pharmacology Public Health Other

Published : 24 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 24 Documents
Search

 1   2   3 
Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis Mida Purwiningtyas; Yulistiani Yulistiani; Budi Suprapti; Bayu Dharma Santi
Folia Medica Indonesiana Vol. 55 No. 4 (2019): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (199.38 KB) | DOI: 10.20473/fmi.v55i4.24494

Abstract

Anemia is a common complication in chronic kidney disease (CKD) patient with hemodialysis. The cause of anemia is mainly due to erythropoetin deficiency because the kidneys as a erythropoetin producer are damaged. The most appropriate management of anemia in CKD with hemodialysis is the administration of Erythropoietin Stimulating Agent (ESA) or erythropoetin (Epo). The effectiveness of Epo therapy is influenced by the type of Epo used, the dose of Epo given, the route and frequency of Epo administration, as well as several conditions that affect it such as infection or inflammation, absolute and functional iron deficiency, and malnutrition. Therapeutic targets can be achieved if the dose given is in accordance with the needs of the patient, based on the patient's weight The purpose of this study was to determine the differences in the achievement of Epo-alpha fixed-dose administration compared with adjustment-dose in patients with CKD anemia with hemodialysis after administration of Epo-alpha for 4 weeks in outpatient poly hemodialysis units at Bhayangkara H.S Hospital. Samsoeri Mertojoso Surabaya. In this study, there were 20 patients who met the inclusion criteria (15 male and 5 female) divided into 2 groups, 10 patients in the fixed-dose group and 10 patients in the adjustment-dose group. In the fixed-dose group with a adequacy level of 132.25 ± 29.17, the average Hb change achievement was 0.68 ± 0.63 g / dL (p=0.008), whereas in the adjustment-dose group the achievement of the average Hb change the mean was 1.09 ± 0.82 g / dL (p=0.002). For the Hct parameter, the average Hct change in the fixed-dose group was 2.77 ± 2.23% (p=0.004), while in the adjustment-dose group the average Hct change achievement was 4.02 ± 2.63 g / dL (p=0.001). There was no difference in the achievement of the effectiveness of Epo on the two parameters Hb (p=0.224) and Hct (p=0.256) in the fixed-dose group compared with adjustment-dose.
Pemberdayaan Pasien dan Keluarga Pasien dalam Pencegahan Amputasi Penderita Diabetes di Kecamatan Mulyorejo Kota Surabaya, Jawa Timur Anggraini Dwi Sensusiati; Budi Suprapti; Marcha Debby Saraswati
Jurnal Pengabdian Pada Masyarakat Vol 6 No 4 (2021)
Publisher : Universitas Mathla'ul Anwar Banten

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30653/002.202164.849

Abstract

EMPOWERMENT OF PATIENTS AND PATIENT FAMILIES IN PREVENTION OF AMPUTATION OF DIABETES IN MULYOREJO DISTRICT, SURABAYA CITY, EAST JAVA PROVINCE. The purpose of implementing this community service program is to empower the community, especially patients and families of diabetes patients, to be able to take steps to prevent disability in diabetes due to amputation. The number of people with diabetes who have to undergo amputation is often influenced by the poor knowledge of diabetes, the low adherence to taking medication, and the poor knowledge and ability of patients and their families in performing wound care for diabetics. In addition, the lack of understanding of diabetes drugs causes the patient to experience side effects that can lead to withdrawal or the patient to experience side effects of hypoglycemia which can put the patient in critical condition. The solution to this problem is to empower diabetes patients and their families. They were given education about diabetes, the importance of taking the medication regularly according to doctor's recommendations, and wound care. In addition, they will be trained on how to do proper wound care for diabetes patients. A medication control post-program will be implemented to ensure that patients will take their medication according to the prescribed guidelines. It is hoped that with this program, the community will understand more about diabetes and its complications to avoiding the disabilities due to amputation by diabetics and patients can avoid unwanted side effects.
PROFIL PENGGUNAAN ANTIKOAGULAN PADA PASIEN COVID-19 DI IRNA FATMAWATI RSUD DR M YUNUS BENGKULU Bella Donna Perdana Putra; Budi Suprapti; Arina Deri Puspita Sari; Mulya Sundari
JURNAL MEDIA KESEHATAN Vol 15 No 1 (2022): Jurnal Media Kesehatan Poltekkes Kemenkes Bengkulu Volume 15 No 1 Juni 2022
Publisher : Politeknik Kesehatan Kemenkes Bengkulu

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33088/jmk.v15i1.741

Abstract

Problems: COVID-19 is a respiratory infection disease caused by SARS-CoV-2. This disease can be transmitted to humans and has spread globally. One of the complication that accompanies COVID-19 is the occurrence of coagulopathy, therefore anticoagulants are used in the treatment of COVID-19. However, studies or reports on the use of anticoagulants in COVID-19 patients have never been carried out by the Research and Development Agency of the Ministry Health Republic Indonesia. The aim of the research: To determine the profile of the use of anticoagulants in COVID-19 patients being treated at IRNA Fatmawati RSUD Dr. M Yunus Bengkulu. Research method: This study is a descriptive observational study with retrospective data collection using a time limited sampling technique, where the data is taken from the medical records of COVID-19 patients being treated at IRNA Fatmawati RSUD Dr M Yunus Bengkulu and met the inclusion criteria in the April 2020–December 2021 period. The results: In this study, 258 medical records of COVID-19 patients met the inclusion criteria, with a greater proportion of male (58.1%) than female (41.9%). The greatest use of anticoagulants was at the age of 56-65 years reaching 37.6%. Fondaparinux was the most widely used anticoagulant (51.2%) followed by heparin (36.8%) and enoxaparin (12.1%). Conclusions: Men aged 56-65 years are more at risk of infection with COVID-19 and coagulopathy complications that require the use of anticoagulants. Keywords: Anticoagulants, Covid-19, Bengkulu Hospital
Isoprinosine along with Favipiravir or Oseltamivir in Patients with Moderate Covid-19 at RSD Dr. Soebandi Jember Chrysnanda Maryska; Didik Hasmono; Sofiati Diah Baisuni; Ayunda Nur Hidayatiningsih; Arina Dery Puspitasari; Retna Dwi Puspitarini; Budi Suprapti
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i32022.209-219

Abstract

Background: Isoprinosine is an immunomodulator that is now being used to treat Covid-19 patients. Objectives: To evaluate Isoprinosine with Favipiravir or Oseltamivir in moderate Covid-19. Methods: In a retrospective observational analysis, in-hospital moderate Covid-19 patients treated between June 2020 and June 2021 were included. Results: Inclusion criteria for 364 patients were met, with 135 receiving Favipiravir-Isoprinosine (Group 1) and 229 receiving Oseltamivir-Isoprinosine (Group 2). In group 1, the majority of patients (58.50%) were female (35.60%), had no comorbidities (71.60%), were discharged with a positive PCR (74.80%), did not require a breathing apparatus (99.26%), had leukocyte levels between 4,5-11,0 (82.22%), lymphocyte levels between 25-33 (34.07%), and were discharged with no ground-glass opacity (34.07%) (54.10%), LOS was 9-13 days (50.37%), while the mortality rate was 0.70%. In group 2, the majority of patients were male (54.10%), with the highest age range being 42-56 years (35.80%), without comorbidities (69.0%), discharged with a positive PCR (72.50 %), and without the need for a breathing apparatus (99.13%), with leukocyte levels ranging from 4.5 – 11.0 (81.22 %), with lymphocyte levels ranging from 25.0 – 33.0 (26.20 %), and were discharged with no ground-glass opacity (49.34 %), LOS was 9 - 13 days (34.06 %), and the mortality rate was 0.87%.Conclusion: In this trial, it was determined that combining isoprinosine with antivirals favipiravir or Oseltamivir could produce significant clinical improvement.
Co-Authors Abdul Rahman Bahmid Aditiawardana Aditiawardana, Aditiawardana Anak Agung Ngurah Putra Riana Prasetya Andarsari, Mareta R. Anggraini Dwi Sensusiati Aniek S. Budiatin Arief Bachtiar Arina Deri Puspita Sari Arina Dery Puspitasari Ayunda Nur Hidayatiningsih Azril O. Ardhiansyah Bayu Dharma Santi Bayu Dharma Shanti Bella Donna Perdana Putra Budiatin, Aniek S. Cahyo Wibisono Chrysnanda Maryska Dewi W. Shinta Dewi W. Shinta Dewi Wara Shinta Didik Hasmono Dwi Hari Susilo Eddy Rahardjo Fathia Ramadiani Hapsari, Pharmasinta P. Hartono, Frenky Hidayati, Movita I Gde Raka Widiana Idha, Arofa Idha, Arofa Junaidi Khotib Khusnul Fitri Hamidah M. Yusuf Assegaf Mahardian Rahmadi Mansur, Mifta Marcha Debby Saraswati Marcha Debby Saraswati Mareta R. Andarsari Mareta Rindang Andarsari Mida Purwiningtyas Mulya Sundari Ni Made Amelia R. Dewi Ni Made Mertaniasih Nia Widyasari Novan Y. I. Pratama Pharmasinta P. Hapsari Pharmasinta Putri Hapsari Prasetya, Anak Agung Ngurah Putra Riana Prastuti Asta Wulaningrum Putranto, J. Nugroho Eko Rahmawati Raising Ramadiani, Fathia Retna Dwi Puspitarini Ria Fitrah Arfiani Santoso, Agustinus Santoso, Agustinus Sarah Puspita Atmaja Shafira Muti Ardiana Shanti, Bayu Dharma Shinta, Dewi W. Sjamsiah, Siti Sjamsiah, Siti Soedarsono Sofiati Diah Baisuni Suharjono Suharjono Suharjono Suharjono Thomas Erwin Christian Junus Huwae Toetik Aryani Tutik Kusmiati UMI FATMAWATI WENNY PUTRI NILAMSARI Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Zamrotul Izzah Zuhri, Muhammad Isnaini